A University of Rhode Island researcher won a National Institutes of Health grant of $1.3 million to further study the use of cancer-targeting copper sulfide nanoparticles for breast cancer.
NanoString Technologies has big plans going forward, and it's now got some extra funding to make those happen. The company has priced its follow-on offering at $55 million, which should give it a boost as it looks to follow up on last quarter's explosive growth.
To make drug delivery structures of a particular size and shape, researchers have developed gold nanoparticle building blocks that can be "glued" together with bits of DNA. This could have particular importance in delivering drugs to treat breast cancer.
Royal Philips on Thursday announced it is the first medical device company to win 510(k) clearance from the FDA for an application to measure breast density as part of routine mammograms. Women with dense breasts--i.e., less fatty tissue--may be at much higher risk of breast cancer.
African-American women who have high levels of a particular protein may be at risk for more aggressive breast cancer and poorer outcomes, according to new research from a Georgia State University study.
Often when using nanoparticles to target and penetrate cancer cells, the shape of the tiny drug-carrying vehicles is crucial to their performance. Researchers have now found evidence that "worm-shaped" nanoparticles may be more effective than spheres at delivering cancer drugs to breast cancer.
A negative test result for certain BRCA2 gene mutations--which increase susceptibility to tumor growth--may not be an accurate indicator of a woman's lower risk for breast cancer.
The FDA has applied its most serious label to Atossa Genetics' recall of a breast cancer diagnostic, warning that using the unapproved devices could lead women to forego treatment and increase their risk of serious injury and death.
A team from IBM Research and the Institute of Bioengineering and Nanotechnology in Singapore have designed a Vitamin E-based hydrogel that can release Roche's cancer antibody Herceptin under the skin for several weeks.
New Jersey's Arno Therapeutics has nailed down a $30 million private placement, cash that'll help the biotech get its treatment for hormone-dependent cancers through Phase I and on the path to FDA approval.